메뉴 건너뛰기




Volumn 87, Issue 3, 2012, Pages 284-293

Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; CHLORAMBUCIL; CLOPIDOGREL; DIPYRIDAMOLE; ERYTHROPOIETIN; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE 2; PEGINTERFERON ALPHA; PHOSPHORUS 32; PIPOBROMAN; ALKYLATING AGENT; ANTICOAGULANT AGENT; JAK2 PROTEIN, HUMAN;

EID: 84856946984     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23135     Document Type: Article
Times cited : (153)

References (115)
  • 1
    • 70349256226 scopus 로고    scopus 로고
    • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    • Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
    • (2009) Blood , vol.114 , pp. 937-951
    • Vardiman, J.W.1    Thiele, J.2    Arber, D.A.3
  • 2
    • 38349101871 scopus 로고    scopus 로고
    • Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms
    • Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
    • (2008) Leukemia , vol.22 , pp. 14-22
    • Tefferi, A.1    Vardiman, J.W.2
  • 3
    • 77954581139 scopus 로고    scopus 로고
    • Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
    • Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010; 24: 1128-1138.
    • (2010) Leukemia. , vol.24 , pp. 1128-1138
    • Tefferi, A.1
  • 4
    • 34548128326 scopus 로고    scopus 로고
    • Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
    • Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21: 1960-1963.
    • (2007) Leukemia , vol.21 , pp. 1960-1963
    • Pardanani, A.1    Lasho, T.L.2    Finke, C.3
  • 5
    • 47649123488 scopus 로고    scopus 로고
    • Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
    • Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22: 1299-1307.
    • (2008) Leukemia , vol.22 , pp. 1299-1307
    • Vannucchi, A.M.1    Antonioli, E.2    Guglielmelli, P.3
  • 6
    • 79960347715 scopus 로고    scopus 로고
    • The JAK2 exon 12 mutations: a comprehensive review
    • Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011; 86: 668-676.
    • (2011) Am J Hematol , vol.86 , pp. 668-676
    • Scott, L.M.1
  • 7
    • 79960343089 scopus 로고    scopus 로고
    • Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis
    • Pardanani A, Lasho TL, Finke CM, et al. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol 2011; 86: 701-702.
    • (2011) Am J Hematol , vol.86 , pp. 701-702
    • Pardanani, A.1    Lasho, T.L.2    Finke, C.M.3
  • 8
    • 77949810252 scopus 로고    scopus 로고
    • Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis
    • Boyd EM, Bench AJ, Goday-Fernandez A, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 149: 250-257.
    • Br J Haematol , vol.149 , pp. 250-257
    • Boyd, E.M.1    Bench, A.J.2    Goday-Fernandez, A.3
  • 9
    • 76449107758 scopus 로고    scopus 로고
    • Two rare MPL gene mutations in patients with essential thrombocythemia
    • Ohashi H, Arita K, Fukami S, et al. Two rare MPL gene mutations in patients with essential thrombocythemia. Int J Hematol 2009; 90: 431-432.
    • (2009) Int J Hematol , vol.90 , pp. 431-432
    • Ohashi, H.1    Arita, K.2    Fukami, S.3
  • 10
    • 47249092413 scopus 로고    scopus 로고
    • MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
    • Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112: 141-149.
    • (2008) Blood , vol.112 , pp. 141-149
    • Beer, P.A.1    Campbell, P.J.2    Scott, L.M.3
  • 11
    • 2542502506 scopus 로고    scopus 로고
    • Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin
    • Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004; 103: 4198-4200.
    • (2004) Blood , vol.103 , pp. 4198-4200
    • Ding, J.1    Komatsu, H.2    Wakita, A.3
  • 12
    • 70349642841 scopus 로고    scopus 로고
    • Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia
    • Liu K, Martini M, Rocca B, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica 2009; 94: 1368-1374.
    • (2009) Haematologica , vol.94 , pp. 1368-1374
    • Liu, K.1    Martini, M.2    Rocca, B.3
  • 13
    • 33750534561 scopus 로고    scopus 로고
    • MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
    • Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
    • (2006) Blood , vol.108 , pp. 3472-3476
    • Pardanani, A.D.1    Levine, R.L.2    Lasho, T.3
  • 14
    • 50949127379 scopus 로고    scopus 로고
    • Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
    • Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008; 112: 844-847.
    • (2008) Blood , vol.112 , pp. 844-847
    • Vannucchi, A.M.1    Antonioli, E.2    Guglielmelli, P.3
  • 15
    • 34047211223 scopus 로고    scopus 로고
    • Anaemia characterises patients with myelofibrosis harbouring Mpl mutation
    • Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007; 137: 244-247.
    • (2007) Br J Haematol , vol.137 , pp. 244-247
    • Guglielmelli, P.1    Pancrazzi, A.2    Bergamaschi, G.3
  • 16
    • 66849103934 scopus 로고    scopus 로고
    • MPLW515L mutation in acute megakaryoblastic leukaemia
    • Hussein K, Bock O, Theophile K, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009; 23: 852-855.
    • (2009) Leukemia , vol.23 , pp. 852-855
    • Hussein, K.1    Bock, O.2    Theophile, K.3
  • 17
    • 66149133661 scopus 로고    scopus 로고
    • Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation
    • Hussein K, Theophile K, Buhr T, Beller A, Kreipe H, Bock O. Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation. Br J Haematol 2009; 145: 673-675.
    • (2009) Br J Haematol , vol.145 , pp. 673-675
    • Hussein, K.1    Theophile, K.2    Buhr, T.3    Beller, A.4    Kreipe, H.5    Bock, O.6
  • 18
    • 38549176801 scopus 로고    scopus 로고
    • JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
    • Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008; 93: 34-40.
    • (2008) Haematologica , vol.93 , pp. 34-40
    • Schmitt-Graeff, A.H.1    Teo, S.S.2    Olschewski, M.3
  • 19
    • 77956439565 scopus 로고    scopus 로고
    • A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
    • Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24: 1574-1579.
    • (2010) Leukemia , vol.24 , pp. 1574-1579
    • Passamonti, F.1    Rumi, E.2    Pietra, D.3
  • 20
    • 80051803115 scopus 로고    scopus 로고
    • Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study
    • Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29: 3179-3184.
    • (2011) J Clin Oncol , vol.29 , pp. 3179-3184
    • Barbui, T.1    Thiele, J.2    Passamonti, F.3
  • 21
    • 79957975519 scopus 로고    scopus 로고
    • Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
    • Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117: 5857-5859.
    • (2011) Blood , vol.117 , pp. 5857-5859
    • Carobbio, A.1    Thiele, J.2    Passamonti, F.3
  • 22
    • 79551607979 scopus 로고    scopus 로고
    • Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
    • Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011; 117: 2813-2816.
    • (2011) Blood. , vol.117 , pp. 2813-2816
    • Passamonti, F.1    Elena, C.2    Schnittger, S.3
  • 23
    • 83555166230 scopus 로고    scopus 로고
    • Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients
    • Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia 2011; 25: 1834-1839.
    • (2011) Leukemia , vol.25 , pp. 1834-1839
    • Pardanani, A.1    Guglielmelli, P.2    Lasho, T.L.3
  • 24
    • 34548042964 scopus 로고    scopus 로고
    • Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
    • Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
    • (2007) Blood , vol.110 , pp. 1092-1097
    • Tefferi, A.1    Thiele, J.2    Orazi, A.3
  • 25
    • 32944477304 scopus 로고    scopus 로고
    • Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia
    • Tefferi A, Sirhan S, Lasho TL, et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 2005; 131: 166-171.
    • (2005) Br J Haematol , vol.131 , pp. 166-171
    • Tefferi, A.1    Sirhan, S.2    Lasho, T.L.3
  • 26
    • 31444439623 scopus 로고    scopus 로고
    • Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis
    • James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006; 20: 350-353.
    • (2006) Leukemia , vol.20 , pp. 350-353
    • James, C.1    Delhommeau, F.2    Marzac, C.3
  • 27
    • 19644392085 scopus 로고    scopus 로고
    • Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis
    • Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004; 89: 1194-1198.
    • (2004) Haematologica , vol.89 , pp. 1194-1198
    • Mossuz, P.1    Girodon, F.2    Donnard, M.3
  • 28
    • 27744606173 scopus 로고    scopus 로고
    • JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance
    • Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208-213.
    • (2005) Br J Haematol , vol.131 , pp. 208-213
    • Wolanskyj, A.P.1    Lasho, T.L.2    Schwager, S.M.3
  • 29
    • 73349117506 scopus 로고    scopus 로고
    • Bone marrow fibrosis and diagnosis of essential thrombocythemia
    • author replye222-e223.
    • Thiele J, Kvasnicka HM, Vardiman JW, et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol 2009; 27: e220-e221; author replye222-e223.
    • (2009) J Clin Oncol , vol.27
    • Thiele, J.1    Kvasnicka, H.M.2    Vardiman, J.W.3
  • 30
    • 74049112732 scopus 로고    scopus 로고
    • Prodromal myeloproliferative neoplasms: the 2008 WHO classification
    • Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010; 85: 62-69.
    • (2010) Am J Hematol , vol.85 , pp. 62-69
    • Kvasnicka, H.M.1    Thiele, J.2
  • 31
    • 4344575770 scopus 로고    scopus 로고
    • Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia
    • Michiels JJ, Berneman Z, Schroyens W, et al. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol 2004; 83: 504-512.
    • (2004) Ann Hematol , vol.83 , pp. 504-512
    • Michiels, J.J.1    Berneman, Z.2    Schroyens, W.3
  • 32
    • 39149105615 scopus 로고    scopus 로고
    • Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment
    • Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438.
    • (2008) Leukemia , vol.22 , pp. 437-438
    • Barosi, G.1    Mesa, R.A.2    Thiele, J.3
  • 33
    • 49449089516 scopus 로고    scopus 로고
    • Evidence and expertise in the management of polycythemia vera and essential thrombocythemia
    • Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 2008; 22: 1494-1502.
    • (2008) Leukemia , vol.22 , pp. 1494-1502
    • Finazzi, G.1    Barbui, T.2
  • 34
    • 55549099571 scopus 로고    scopus 로고
    • Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
    • Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008; 93: 1645-1651.
    • (2008) Haematologica , vol.93 , pp. 1645-1651
    • Passamonti, F.1    Rumi, E.2    Arcaini, L.3
  • 35
    • 8344229870 scopus 로고    scopus 로고
    • Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
    • Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117: 755-761.
    • (2004) Am J Med , vol.117 , pp. 755-761
    • Passamonti, F.1    Rumi, E.2    Pungolino, E.3
  • 36
    • 34447132275 scopus 로고    scopus 로고
    • Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
    • Gangat N, Strand J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007; 138: 354-358.
    • (2007) Br J Haematol , vol.138 , pp. 354-358
    • Gangat, N.1    Strand, J.2    Li, C.Y.3
  • 37
    • 33845900474 scopus 로고    scopus 로고
    • The haematocrit and platelet target in polycythemia vera
    • Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007; 136: 249-259.
    • (2007) Br J Haematol , vol.136 , pp. 249-259
    • Di Nisio, M.1    Barbui, T.2    Di Gennaro, L.3
  • 38
    • 0021683781 scopus 로고
    • Acquired von Willebrand's disease in the myeloproliferative syndrome
    • Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64: 981-985.
    • (1984) Blood , vol.64 , pp. 981-985
    • Budde, U.1    Schaefer, G.2    Mueller, N.3
  • 39
    • 33846540216 scopus 로고    scopus 로고
    • Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients
    • Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270-276.
    • (2007) Leukemia , vol.21 , pp. 270-276
    • Gangat, N.1    Wolanskyj, A.P.2    McClure, R.F.3
  • 40
    • 75449101962 scopus 로고    scopus 로고
    • Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain
    • Tefferi A. Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain. Am J Hematol 2009; 85: 93-94.
    • (2009) Am J Hematol , vol.85 , pp. 93-94
    • Tefferi, A.1
  • 41
    • 67649402606 scopus 로고    scopus 로고
    • Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
    • Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009; 114: 759-763.
    • (2009) Blood , vol.114 , pp. 759-763
    • Barbui, T.1    Carobbio, A.2    Rambaldi, A.3    Finazzi, G.4
  • 42
    • 70349479426 scopus 로고    scopus 로고
    • Essential thrombocythemia and pregnancy: observations from recent studies and management recommendations
    • Tefferi A, Passamonti F. Essential thrombocythemia and pregnancy: observations from recent studies and management recommendations. Am J Hematol 2009; 84: 629-630.
    • (2009) Am J Hematol , vol.84 , pp. 629-630
    • Tefferi, A.1    Passamonti, F.2
  • 43
    • 74749098378 scopus 로고    scopus 로고
    • Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies
    • Passamonti F, Rumi E, Randi ML, et al. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. J Thromb Haemost 2010; 8: 411-413.
    • (2010) J Thromb Haemost , vol.8 , pp. 411-413
    • Passamonti, F.1    Rumi, E.2    Randi, M.L.3
  • 44
    • 64249116813 scopus 로고    scopus 로고
    • Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies
    • Gangat N, Wolanskyj AP, Schwager S, et al. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol 2009; 82: 350-353.
    • (2009) Eur J Haematol , vol.82 , pp. 350-353
    • Gangat, N.1    Wolanskyj, A.P.2    Schwager, S.3
  • 45
    • 77953068974 scopus 로고    scopus 로고
    • A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs
    • Crisa E, Venturino E, Passera R, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol 2010; 89: 691-699.
    • (2010) Ann Hematol , vol.89 , pp. 691-699
    • Crisa, E.1    Venturino, E.2    Passera, R.3
  • 46
    • 34249949626 scopus 로고    scopus 로고
    • Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
    • Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33: 313-320.
    • (2007) Semin Thromb Hemost , vol.33 , pp. 313-320
    • Tefferi, A.1    Elliott, M.2
  • 47
    • 0035672739 scopus 로고    scopus 로고
    • Pruritus in polycythaemia vera: prevalence, laboratory correlates and management
    • Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol 2001; 115: 619-621.
    • (2001) Br J Haematol , vol.115 , pp. 619-621
    • Diehn, F.1    Tefferi, A.2
  • 48
    • 33749028699 scopus 로고    scopus 로고
    • The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera
    • Michiels JJ, Berneman Z, Schroyens W, et al. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006; 32: 589-604.
    • (2006) Semin Thromb Hemost , vol.32 , pp. 589-604
    • Michiels, J.J.1    Berneman, Z.2    Schroyens, W.3
  • 49
    • 0346727336 scopus 로고    scopus 로고
    • Efficacy and safety of low-dose aspirin in polycythemia vera
    • Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-124.
    • (2004) N Engl J Med , vol.350 , pp. 114-124
    • Landolfi, R.1    Marchioli, R.2    Kutti, J.3
  • 50
    • 77956524019 scopus 로고    scopus 로고
    • Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
    • quiz 1387.
    • Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116: 1205-1210; quiz 1387.
    • (2010) Blood , vol.116 , pp. 1205-1210
    • Alvarez-Larran, A.1    Cervantes, F.2    Pereira, A.3
  • 51
    • 0001148171 scopus 로고
    • Complications and causes of death in polycythemia vera
    • Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand 1962; 172: 513-523.
    • (1962) Acta Med Scand , vol.172 , pp. 513-523
    • Chievitz, E.1    Thiede, T.2
  • 52
    • 33751507891 scopus 로고    scopus 로고
    • Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia
    • Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006; 17: 528-544.
    • (2006) Platelets , vol.17 , pp. 528-544
    • Michiels, J.J.1    Berneman, Z.2    Schroyens, W.3
  • 53
    • 0021914091 scopus 로고
    • Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia
    • Michiels JJ, Abels J, Steketee J, et al. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985; 102: 466-471.
    • (1985) Ann Intern Med , vol.102 , pp. 466-471
    • Michiels, J.J.1    Abels, J.2    Steketee, J.3
  • 54
    • 0029847674 scopus 로고    scopus 로고
    • Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation
    • van Genderen PJ, Lucas IS, van Strik R, et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost 1996; 76: 333-338.
    • (1996) Thromb Haemost , vol.76 , pp. 333-338
    • van Genderen, P.J.1    Lucas, I.S.2    van Strik, R.3
  • 55
    • 0028831268 scopus 로고
    • Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin
    • van Genderen PJ, Michiels JJ, van Strik R, et al. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost 1995; 73: 210-214.
    • (1995) Thromb Haemost , vol.73 , pp. 210-214
    • van Genderen, P.J.1    Michiels, J.J.2    van Strik, R.3
  • 56
    • 9444297296 scopus 로고    scopus 로고
    • Pregnancy in essential thrombocythaemia: experience with 40 pregnancies
    • Niittyvuopio R, Juvonen E, Kaaja R, et al. Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. Eur J Haematol 2004; 73: 431-436.
    • (2004) Eur J Haematol , vol.73 , pp. 431-436
    • Niittyvuopio, R.1    Juvonen, E.2    Kaaja, R.3
  • 57
    • 0035062679 scopus 로고    scopus 로고
    • A single institutional experience with 43 pregnancies in essential thrombocythemia
    • Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 2001; 66: 152-159.
    • (2001) Eur J Haematol , vol.66 , pp. 152-159
    • Wright, C.A.1    Tefferi, A.2
  • 58
    • 34547122759 scopus 로고    scopus 로고
    • Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
    • Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 2007; 110: 485-489.
    • (2007) Blood , vol.110 , pp. 485-489
    • Passamonti, F.1    Randi, M.L.2    Rumi, E.3
  • 59
    • 33745714752 scopus 로고    scopus 로고
    • Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe
    • Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost 2006; 32: 422-429.
    • (2006) Semin Thromb Hemost , vol.32 , pp. 422-429
    • Griesshammer, M.1    Struve, S.2    Harrison, C.M.3
  • 60
    • 0035062679 scopus 로고    scopus 로고
    • A single institutional experience with 43 pregnancies in essential thrombocythemia
    • Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 2001; 66: 152-159.
    • (2001) Eur J Haematol , vol.66 , pp. 152-159
    • Wright, C.A.1    Tefferi, A.2
  • 62
    • 84856877076 scopus 로고    scopus 로고
    • Pruritus in primary myelofibrosis: clinical and laboratory correlates
    • Vaa BE, Wolanskyj AP, Roeker L, et al. Pruritus in primary myelofibrosis: clinical and laboratory correlates. Am J Hematol 2011.
    • (2011) Am J Hematol
    • Vaa, B.E.1    Wolanskyj, A.P.2    Roeker, L.3
  • 63
    • 0036530037 scopus 로고    scopus 로고
    • Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus
    • Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002; 99: 2627.
    • (2002) Blood , vol.99 , pp. 2627
    • Tefferi, A.1    Fonseca, R.2
  • 64
    • 79751532774 scopus 로고    scopus 로고
    • JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
    • Pardanani A, Vannucchi AM, Passamonti F, et al. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011; 25: 218-225.
    • (2011) Leukemia , vol.25 , pp. 218-225
    • Pardanani, A.1    Vannucchi, A.M.2    Passamonti, F.3
  • 65
    • 0028966729 scopus 로고
    • Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera
    • Muller EW, de Wolf JT, Egger R, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Br J Haematol 1995; 89: 313-318.
    • (1995) Br J Haematol , vol.89 , pp. 313-318
    • Muller, E.W.1    de Wolf, J.T.2    Egger, R.3
  • 66
    • 0036436854 scopus 로고    scopus 로고
    • Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera
    • Baldo A, Sammarco E, Plaitano R, et al. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol 2002; 147: 979-981.
    • (2002) Br J Dermatol , vol.147 , pp. 979-981
    • Baldo, A.1    Sammarco, E.2    Plaitano, R.3
  • 67
    • 46049099572 scopus 로고    scopus 로고
    • The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation
    • Kayacioglu I, Gunay R, Saskin H, et al. The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation. Heart Surg Forum 2008; 11: E152-E157.
    • (2008) Heart Surg Forum , vol.11
    • Kayacioglu, I.1    Gunay, R.2    Saskin, H.3
  • 68
    • 21444434751 scopus 로고    scopus 로고
    • Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
    • Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45.
    • (2005) N Engl J Med , vol.353 , pp. 33-45
    • Harrison, C.N.1    Campbell, P.J.2    Buck, G.3
  • 69
    • 79952333359 scopus 로고    scopus 로고
    • Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
    • Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789-796.
    • (2011) J Clin Oncol , vol.29 , pp. 789-796
    • Pardanani, A.1    Gotlib, J.R.2    Jamieson, C.3
  • 70
    • 0022862698 scopus 로고
    • Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome
    • Budde U, Dent JA, Berkowitz SD, et al. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1986; 68: 1213-1217.
    • (1986) Blood , vol.68 , pp. 1213-1217
    • Budde, U.1    Dent, J.A.2    Berkowitz, S.D.3
  • 71
    • 0023644025 scopus 로고
    • Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis
    • Lopez-Fernandez MF, Lopez-Berges C, Martin R, et al. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis. Thromb Haemost 1987; 58: 753-757.
    • (1987) Thromb Haemost , vol.58 , pp. 753-757
    • Lopez-Fernandez, M.F.1    Lopez-Berges, C.2    Martin, R.3
  • 72
    • 0029878123 scopus 로고    scopus 로고
    • Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion
    • Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244.
    • (1996) Blood , vol.87 , pp. 4235-4244
    • Tsai, H.M.1
  • 73
    • 0035807348 scopus 로고    scopus 로고
    • Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura
    • Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
    • (2001) Nature , vol.413 , pp. 488-494
    • Levy, G.G.1    Nichols, W.C.2    Lian, E.C.3
  • 74
    • 0034911766 scopus 로고    scopus 로고
    • Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management
    • Michiels JJ, Budde U, van der Planken M, et al. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Baillieres Best Pract Res Clin Haematol 2001; 14: 401-436.
    • (2001) Baillieres Best Pract Res Clin Haematol , vol.14 , pp. 401-436
    • Michiels, J.J.1    Budde, U.2    van der Planken, M.3
  • 75
    • 0029951483 scopus 로고    scopus 로고
    • The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count
    • van Genderen PJ, Budde U, Michiels JJ, et al. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 1996; 93: 962-965.
    • (1996) Br J Haematol , vol.93 , pp. 962-965
    • van Genderen, P.J.1    Budde, U.2    Michiels, J.J.3
  • 76
    • 0031472388 scopus 로고    scopus 로고
    • Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count
    • van Genderen PJ, Prins FJ, Lucas IS, et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol 1997; 99: 832-836.
    • (1997) Br J Haematol , vol.99 , pp. 832-836
    • van Genderen, P.J.1    Prins, F.J.2    Lucas, I.S.3
  • 77
    • 0033985083 scopus 로고    scopus 로고
    • Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source
    • Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000; 83: 127-135.
    • (2000) Thromb Haemost , vol.83 , pp. 127-135
    • Favaloro, E.J.1
  • 78
    • 0025048792 scopus 로고
    • A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders
    • Wehmeier A, Fricke S, Scharf RE, et al. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Haematol 1990; 45: 191-197.
    • (1990) Eur J Haematol , vol.45 , pp. 191-197
    • Wehmeier, A.1    Fricke, S.2    Scharf, R.E.3
  • 79
    • 0024436976 scopus 로고
    • Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease
    • Wehmeier A, Scharf RE, Fricke S, et al. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease. Haemostasis 1989; 19: 251-259.
    • (1989) Haemostasis , vol.19 , pp. 251-259
    • Wehmeier, A.1    Scharf, R.E.2    Fricke, S.3
  • 80
    • 0024465571 scopus 로고
    • Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders
    • Gersuk GM, Carmel R, Pattengale PK. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Blood 1989; 74: 2330-2334.
    • (1989) Blood , vol.74 , pp. 2330-2334
    • Gersuk, G.M.1    Carmel, R.2    Pattengale, P.K.3
  • 81
    • 0021280322 scopus 로고
    • Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis
    • Burstein SA, Malpass TW, Yee E, et al. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis. Br J Haematol 1984; 57: 383-392.
    • (1984) Br J Haematol , vol.57 , pp. 383-392
    • Burstein, S.A.1    Malpass, T.W.2    Yee, E.3
  • 82
    • 0025765842 scopus 로고
    • Circulating activated platelets in myeloproliferative disorders
    • Wehmeier A, Tschope D, Esser J, et al. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991; 61: 271-278.
    • (1991) Thromb Res , vol.61 , pp. 271-278
    • Wehmeier, A.1    Tschope, D.2    Esser, J.3
  • 83
    • 0018163875 scopus 로고
    • Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelha-adrenergic receptors
    • Kaywin P, McDonough M, Insel PA, et al. Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N Engl J Med 1978; 299: 505-509.
    • (1978) N Engl J Med , vol.299 , pp. 505-509
    • Kaywin, P.1    McDonough, M.2    Insel, P.A.3
  • 84
    • 0024403073 scopus 로고
    • Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function
    • Mazzucato M, De Marco L, De Angelis V, et al. Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol 1989; 73: 369-374.
    • (1989) Br J Haematol , vol.73 , pp. 369-374
    • Mazzucato, M.1    De Marco, L.2    De Angelis, V.3
  • 85
    • 0032530687 scopus 로고    scopus 로고
    • Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera
    • Le Blanc K, Lindahl T, Rosendahl K, et al. Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. Thromb Res 1998; 91: 287-295.
    • (1998) Thromb Res , vol.91 , pp. 287-295
    • Le Blanc, K.1    Lindahl, T.2    Rosendahl, K.3
  • 86
    • 0033871736 scopus 로고    scopus 로고
    • Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders.[see comment]
    • Jensen MK, de Nully Brown P, Lund BV, et al. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders.[see comment]. Br J Haematol 2000; 110: 116-124.
    • (2000) Br J Haematol , vol.110 , pp. 116-124
    • Jensen, M.K.1    de Nully Brown, P.2    Lund, B.V.3
  • 87
    • 77954941157 scopus 로고    scopus 로고
    • Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count
    • Tefferi A, Smock KJ, Divgi AB. Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count. Am J Hematol 2010; 85: 545.
    • (2010) Am J Hematol , vol.85 , pp. 545
    • Tefferi, A.1    Smock, K.J.2    Divgi, A.B.3
  • 88
    • 0019378211 scopus 로고
    • Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy
    • Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441-447.
    • (1981) N Engl J Med , vol.304 , pp. 441-447
    • Berk, P.D.1    Goldberg, J.D.2    Silverstein, M.N.3
  • 89
    • 0002596838 scopus 로고
    • Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group
    • Wasserman LR,Berk PD,Berlin NI, editors. Philadelphia: W.B. Saunders
    • Berk PD, Wasserman LR, Fruchtman SM, et al. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI, editors. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia: W.B. Saunders; 1995. pp 166-194.
    • (1995) Polycythemia Vera and the Myeloproliferative Disorders , pp. 166-194
    • Berk, P.D.1    Wasserman, L.R.2    Fruchtman, S.M.3
  • 90
    • 0019488158 scopus 로고
    • Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial
    • quot;Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.)
    • "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Br J Cancer 1981; 44: 75-80.
    • (1981) Br J Cancer , vol.44 , pp. 75-80
  • 91
    • 0030784247 scopus 로고    scopus 로고
    • Treatment of polycythemia vera - the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years
    • Najean Y, Rain JD. Treatment of polycythemia vera - the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370-3377.
    • (1997) Blood , vol.90 , pp. 3370-3377
    • Najean, Y.1    Rain, J.D.2
  • 92
    • 80053945428 scopus 로고    scopus 로고
    • Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980
    • Kiladjian JJ, Chevret S, Dosquet C, et al.. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011; 29: 3907-3913.
    • (2011) J Clin Oncol , vol.29 , pp. 3907-3913
    • Kiladjian, J.J.1    Chevret, S.2    Dosquet, C.3
  • 93
    • 0031000705 scopus 로고    scopus 로고
    • Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age
    • The French Polycythemia Study Group
    • Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997; 89: 2319-2327.
    • (1997) Blood , vol.89 , pp. 2319-2327
    • Najean, Y.1    Rain, J.D.2
  • 94
    • 0022743990 scopus 로고
    • Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera
    • Tartaglia AP, Goldberg JD, Berk PD, et al. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986; 23: 172-176.
    • (1986) Semin Hematol , vol.23 , pp. 172-176
    • Tartaglia, A.P.1    Goldberg, J.D.2    Berk, P.D.3
  • 95
    • 3042513955 scopus 로고    scopus 로고
    • A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP)
    • Finazzi G. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol (Paris) 2004; 52: 285-288.
    • (2004) Pathol Biol (Paris) , vol.52 , pp. 285-288
    • Finazzi, G.1
  • 96
    • 0028913012 scopus 로고
    • Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
    • Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132-1136.
    • (1995) N Engl J Med , vol.332 , pp. 1132-1136
    • Cortelazzo, S.1    Finazzi, G.2    Ruggeri, M.3
  • 97
    • 79951899119 scopus 로고    scopus 로고
    • Anahydret: a European multicenter prospective phase 3-study: non-inferiority of anagrelide compared to hydroxyurea in newly who diagnosed Et patients
    • Petrides E, Gotic M, Penka M, et al. Anahydret: a European multicenter prospective phase 3-study: non-inferiority of anagrelide compared to hydroxyurea in newly who diagnosed Et patients. Haematol Hematol J 2009; 94: 440.
    • (2009) Haematol Hematol J , vol.94 , pp. 440
    • Petrides, E.1    Gotic, M.2    Penka, M.3
  • 98
    • 0031041044 scopus 로고    scopus 로고
    • From efficacy to safety - a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera
    • Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety - a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34: 17-23.
    • (1997) Semin Hematol , vol.34 , pp. 17-23
    • Fruchtman, S.M.1    Mack, K.2    Kaplan, M.E.3
  • 99
    • 0023279929 scopus 로고
    • Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period
    • West WO. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period. South Med J 1987; 80: 323-327.
    • (1987) South Med J , vol.80 , pp. 323-327
    • West, W.O.1
  • 100
    • 0031047488 scopus 로고    scopus 로고
    • Management of polycythemia vera with hydroxyurea
    • Tatarsky I, Sharon R. Management of polycythemia vera with hydroxyurea. Semin Hematol 1997; 34: 24-28.
    • (1997) Semin Hematol , vol.34 , pp. 24-28
    • Tatarsky, I.1    Sharon, R.2
  • 101
    • 20144389274 scopus 로고    scopus 로고
    • Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study
    • Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera. An analysis of 1, 638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664-2670.
    • (2005) Blood , vol.105 , pp. 2664-2670
    • Finazzi, G.1    Caruso, V.2    Marchioli, R.3
  • 102
    • 0033757965 scopus 로고    scopus 로고
    • Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients
    • Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 2000; 85: 1011-1018.
    • (2000) Haematologica , vol.85 , pp. 1011-1018
    • Passamonti, F.1    Brusamolino, E.2    Lazzarino, M.3
  • 103
    • 0031804798 scopus 로고    scopus 로고
    • Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991)
    • Petti MC, Spadea A, Avvisati G, et al. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). Leukemia 1998; 12: 869-874.
    • (1998) Leukemia , vol.12 , pp. 869-874
    • Petti, M.C.1    Spadea, A.2    Avvisati, G.3
  • 104
    • 0242266434 scopus 로고    scopus 로고
    • Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution
    • De Sanctis V, Mazzucconi MG, Spadea A, et al. Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. Br J Haematol 2003; 123: 517-521.
    • (2003) Br J Haematol , vol.123 , pp. 517-521
    • De Sanctis, V.1    Mazzucconi, M.G.2    Spadea, A.3
  • 105
    • 4344655346 scopus 로고    scopus 로고
    • Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman
    • Passamonti F, Rumi E, Malabarba L, et al. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Ann Hematol 2004; 83: 495-497.
    • (2004) Ann Hematol , vol.83 , pp. 495-497
    • Passamonti, F.1    Rumi, E.2    Malabarba, L.3
  • 106
    • 0022400901 scopus 로고
    • Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre
    • Messinezy M, Pearson TC, Prochazka A, et al. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol 1985; 61: 657-666.
    • (1985) Br J Haematol , vol.61 , pp. 657-666
    • Messinezy, M.1    Pearson, T.C.2    Prochazka, A.3
  • 107
    • 0023075539 scopus 로고
    • Treatment of primary proliferative polycythaemia by venesection and busulphan
    • D'Emilio A, Battista R, Dini E. Treatment of primary proliferative polycythaemia by venesection and busulphan. Br J Haematol 1987; 65: 121-122.
    • (1987) Br J Haematol , vol.65 , pp. 121-122
    • D'Emilio, A.1    Battista, R.2    Dini, E.3
  • 108
    • 0031982894 scopus 로고    scopus 로고
    • Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion
    • Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616-622.
    • (1998) Blood , vol.91 , pp. 616-622
    • Sterkers, Y.1    Preudhomme, C.2    Lai, J.L.3
  • 109
    • 34548125318 scopus 로고    scopus 로고
    • Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia
    • Shvidel L, Sigler E, Haran M, et al. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. Leukemia 2007; 21: 2071-2072.
    • (2007) Leukemia , vol.21 , pp. 2071-2072
    • Shvidel, L.1    Sigler, E.2    Haran, M.3
  • 110
    • 56249104095 scopus 로고    scopus 로고
    • Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms
    • Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22: 1990-1998.
    • (2008) Leukemia , vol.22 , pp. 1990-1998
    • Kiladjian, J.J.1    Chomienne, C.2    Fenaux, P.3
  • 111
    • 73949090770 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
    • Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27: 5418-5424.
    • (2009) J Clin Oncol , vol.27 , pp. 5418-5424
    • Quintas-Cardama, A.1    Kantarjian, H.2    Manshouri, T.3
  • 112
    • 54049141336 scopus 로고    scopus 로고
    • Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
    • Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-3072.
    • (2008) Blood , vol.112 , pp. 3065-3072
    • Kiladjian, J.J.1    Cassinat, B.2    Chevret, S.3
  • 113
    • 77950622293 scopus 로고    scopus 로고
    • The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)
    • Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010; 115: 2354-2363.
    • (2010) Blood , vol.115 , pp. 2354-2363
    • Voskaridou, E.1    Christoulas, D.2    Bilalis, A.3
  • 114
    • 24944524079 scopus 로고    scopus 로고
    • European consensus on grading bone marrow fibrosis and assessment of cellularity
    • Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128-1132.
    • (2005) Haematologica , vol.90 , pp. 1128-1132
    • Thiele, J.1    Kvasnicka, H.M.2    Facchetti, F.3
  • 115
    • 0018675904 scopus 로고
    • The reticulin content of bone marrow in acute leukaemia in adults
    • Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979; 43: 185-190.
    • (1979) Br J Haematol , vol.43 , pp. 185-190
    • Manoharan, A.1    Horsley, R.2    Pitney, W.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.